Please take note below of Wellcome Trust’s (UK) webinar on tips for applying to their International Masters, Training and Intermediate Fellowships. The next due dates for applications are:
Our EDCTP Fellows have been very active across the continent in the response to the COVID-19 pandemic. Many countries around the world have been in varying degrees of lockdown and have relied heavily on advice from medical specialists, epidemiologists and researchers to guide their response. Please read our EDCTP monthly updates as we showcase the work of our Fellows each month https://www.edctp.org/web/app/uploads/2020/08/EDCTP-Update-July-2020.pdf
Bourema Kouriba - COVID-19 diagnosis in Mali
Professor Bourema Kouriba (a former EDCTP1 senior Fellow) is a pharmacist, immunologist, and the Director General of the Charles Mérieux Centre for Infectiology (CMCI) in Bamako, Mali. He leads a team responsible for diagnostics of emerging and re-emerging infectious diseases and teaches immunology at the Faculties of Medicine and Pharmacy in Bamako.
Since the Ebola epidemic in 2014, the institute developed its diagnostics capabilities with the support of the Institute of Microbiology of the German Army. The German government donated a mobile laboratory to the Malian Ministry of Health under the responsibility of CMCI, which participates with the National Institute of Public Health in epidemiological surveillance and the response to epidemics. Professor Kouriba: "On the outbreak of the COVID-19 pandemic in March 2020, CMCI and three other
centres were appointed by the Ministry of Health and Social Affairs to carry out the diagnostic side. Right now, we are in Timbuktu, a town in the north at 900 km from the capital Bamako. Here, our mobile laboratory is deployed to carry out the COVID19 molecular diagnostic tests. The day begins with the preparation of bleach solutions. Then we organise the team in the different workstations: one person at the reception, two people in the glove box, one person at the RNA extraction and the preparation of the master mix and another at the amplification."
"I take care of entering data and editing the results personally. As soon as the samples are received, their number is counted and communicated to the entire team. Once received, samples are conditioned in a container and transferred to the glove box team whose role is to inactivate these samples. This inactivation is carried out under the control of a witness who notes on the patient form all the steps performed by the operator. After inactivation, the samples are removed from the glove box for RNA extraction. At the same time, one person responsible for preparing the master mix prepares the necessary quantity of reagent. The last step is the real-time PCR. After two hours the results are analysed, interpreted, entered into the
database and printed for the doctor. At the end of the day, the glove compartment and the equipment are cleaned with concentrated bleach." There are several serious challenges:
1. The situation of consumables used for PCR, in particular for extraction kits. With the borders closed, the supply of reagents and consumables in the country is a very big challenge.
2. We receive most of our reagents through donors as the government cannot afford to buy them. Each donor buys reagents, which poses a problem for having a uniform algorithm to interpret the results.
3. Non-compliance with distancing and prevention measures which increases the number of contact cases, hence the number of samples to be tested per day. The laboratory works at least 10 hours a day to meet demand.
"We are in an unprecedented pandemic against which we are actually learning and responding at the same time. Timbuktu is in the north in an insecure area of Mali and the temperature fluctuates between 42 and 46 degrees Celsius. But it is our population and we must guarantee equity in access to care. Everyone should take this pandemic seriously and show solidarity with countries with limited resources because SARS-COV2 does not know borders and does not differentiate between people. Countries must be united in the fight against COVID-19."
Recognizing the urgent need for collaboration, cooperation, and coordination to ensure that Africa plays a leadership role in the development and access to potential vaccines, this two-day virtual conference, under the leadership of H.E. Moussa Faki Mahamat, Chairperson of the African Union Commission (AUC), will bring together healthcare professionals, researchers, public health experts, policy makers, media, civil society, community and religious leaders, and industries to explore this topic and help develop a framework for COVID-19 vaccine development and access in Africa.
When: Jun 24, 2020 02:00 PM and Jun 25, 2020 01:00 PM Nairobi
Topic: Africa’s Leadership in COVID-19 Vaccine Development and Access
TO REGISTER VISIT: https://bit.ly/2B6BXvA Register in advance for this webinar. After registering, you will receive a confirmation email containing information about joining the webinar.
A call for nominations for experts to serve on a Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines and Vaccination has been posted on the SAGE website: https://www.who.int/immunization/policy/sage/en/
This SAGE working group will be set up with the aim of establishing an independent process through SAGE to advise WHO and its Member States on the use of initially pre-licensed vaccines, followed by updates as additional information on product use becomes available. The timeliness of setting up this group will ensure a coordinated approach with the vaccine Research and Development (R&D) community, in order to accelerate timelines and maximize global efforts to make evidence-informed policy decisions for the best use of a vaccine against COVID-19. The ultimate goal of a vaccine against COVID-19 is to rapidly contain the pandemic, save lives, protect health care systems, and restore global economies.
The SAGE Working Group is established with a program of work to:
(1) Provide continuous review of the available evidence on the progress of candidate vaccines against COVID-19, and provide regular updates to SAGE;
(2) Provide guidance for the development of prediction models to determine the optimal age groups and target populations for vaccine introduction and guide vaccine introduction for optimal impact, and contribute to updates of target product profiles of vaccines for outbreak and for endemic use;
(3) Prepare policy advice to SAGE on the accelerated use of vaccines (pre-licensure and post-licensure) to mitigate the public health impact of COVID-19, to possibly curtail the ongoing pandemic, as well as to prevent or reduce the risk of spread of disease in the future. This will include recommendations for early allocation of vaccines when vaccine supply is still limited;
(4) Provide guidance to ensure equitable access to vaccination, and guidance on the safety of vaccines when safety data from wider population use become available, in close collaboration with Global Advisory Committee on Vaccine Safety (GACVS).